---
title: Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy
date: '2023-10-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37809078/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231009180720&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: AML is a malignant disease of hematopoietic progenitor cells with unsatisfactory
  treatment outcome, especially in patients that are ineligible for intensive chemotherapy.
  Immunotherapy, comprising checkpoint inhibition, T-cell engaging antibody constructs,
  and cellular therapies, has dramatically improved the outcome of patients with solid
  tumors and lymphatic neoplasms. In AML, these approaches have been far less successful.
  Discussed reasons are the relatively low mutational burden of ...
disable_comments: true
---
AML is a malignant disease of hematopoietic progenitor cells with unsatisfactory treatment outcome, especially in patients that are ineligible for intensive chemotherapy. Immunotherapy, comprising checkpoint inhibition, T-cell engaging antibody constructs, and cellular therapies, has dramatically improved the outcome of patients with solid tumors and lymphatic neoplasms. In AML, these approaches have been far less successful. Discussed reasons are the relatively low mutational burden of ...